Alexion Pharmaceuticals has appointed Judith Reinsdorf to its board of directors following her role as executive vice president and general counsel of Johnson Controls.
Reinsdorf, who has a background in corporate governance and expertise in managing corporate and legal affairs, has served in various positions for companies including Tyco International and Monsanto.
David Brennan, chairman of the board, said: “We are pleased to welcome Judy to Alexion’s board of directors.
“She brings strong corporate governance and legal expertise, with a proven track records in global compliance, strategic planning, data privacy and regulatory matters.
“Her broad experience at large US public companies, both within and outside the healthcare industry, will be a valuable addition to our board.”
Reinsdorf joins at a time when the company aims to “strengthen its leadership position in rare diseases”.
She said: “I am excited to join Alexion’s board of directors at a pivotal time for the company as it executes its strategy to deliver sustainable growth and I look forward to applying my experience to help guide Alexion’s future success.”
In addition, director Ann Veneman has also announced that she does not plan to stand for re-election as she will be retiring following eight years of service.